Related Experiment Video
Updated: Jun 10, 2026
09:02
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
[Oral molecular targeting agents in hematological malignancy].
Shihoko Wakabayashi1, Kazuteru Ohashi
1Department of Hematology, Tokyo Metropolitan Infectious Disease Center Komagome Hospital, Tokyo, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 22, 2010
Summary
Molecular targeted therapies offer promising treatments for blood cancers like chronic myeloid leukemia (CML), acute promyelocytic leukemia (APL), and multiple myeloma (MM). New drugs provide effective options for patients with resistant or relapsed conditions.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Context:
- Molecular targeted therapy represents a significant advancement in treating hematological malignancies.
- Chronic myeloid leukemia (CML) management has been revolutionized by imatinib, with long-term data showing high efficacy and tolerability.
- Alternative therapies like dasatinib and nilotinib are available for imatinib-resistant cases.
Purpose:
- To provide a comprehensive review of current molecular targeted therapies for CML, APL, and MM.
- To present data supporting the efficacy of these targeted treatments.
- To highlight advancements in managing hematological malignancies through molecular approaches.
Summary:
- Imatinib is the standard for chronic-phase CML, with second-generation inhibitors available for resistance.
- Acute promyelocytic leukemia (APL) treatment has shifted to differentiation therapy, combining all-trans retinoic acid (ATRA) with chemotherapy.
- Thalidomide and lenalidomide offer new treatment avenues for multiple myeloma (MM), including relapsed/refractory cases.
Impact:
- Molecular targeted therapies have improved long-term outcomes and quality of life for patients with CML, APL, and MM.
- The development of targeted agents signifies a paradigm shift from conventional chemotherapy to precision medicine in hematologic oncology.
- This review underscores the growing importance and success of molecularly-driven treatment strategies in combating blood cancers.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...